In a report released yesterday, Suraj Kalia from Oppenheimer maintained a Sell rating on Inspire Medical Systems (INSP), with a price target of $50.00. The company’s shares closed last Monday at $78.53, close to its 52-week high of $83.71.
According to TipRanks.com, Kalia is a 4-star analyst with an average return of 5.7% and a 52.8% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Edwards Lifesciences, and Strata Skin Sciences.
Inspire Medical Systems has an analyst consensus of Hold, with a price target consensus of $70.00.
See today’s analyst top recommended stocks >>
Based on Inspire Medical Systems’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $8.25 million. In comparison, last year the company had a GAAP net loss of $4.78 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inspire Medical Systems, Inc. engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. The company was founded by Timothy P.
